肾移植受者口服缬更昔洛韦预防用药的药代动力学及基于模型的最优给药方案预测
该研究回顾性收集97例成人肾移植受者10年TDM数据(792个更昔洛韦浓度),建立一室口服吸收群体药代动力学模型,发现更昔洛韦清除率随肌酐清除率变化。蒙特卡洛模拟显示按肾功能调整的推荐预防剂量在CLCR<50 mL/min者达到AUC 40-50 mg·h/L的概率不足,建议提高按肾功能校正的剂量。
要点
- 更昔洛韦清除率与肌酐清除率相关,模型为CL=TVCL×(CLCR/51)^0.75。
- 推荐预防剂量在肾功能受损(CLCR<50 mL/min)者达到AUC目标的概率不足。
- 建议肾移植受者口服预防采用更高、按肾功能校正的缬更昔洛韦剂量。
核心结论
- 肾移植受者口服缬更昔洛韦预防CMV感染时,建议采用更高且按肾功能校正的剂量。
- 需进一步研究确立TDM目标,以保证有效浓度并避免潜在毒性暴露。
研究设计与样本
- 回顾性收集成人肾移植受者10年TDM数据,共97例患者、792个更昔洛韦浓度测量值。
- 采用Pmetrics™包进行非参数群体药代动力学分析及蒙特卡洛模拟。
主要发现
- 一室口服吸收模型最佳描述数据。
- 最终协变量模型为CL(更昔洛韦)=TVCL×(CLCR/51)^0.75,CLCR按Cockcroft-Gault方程计算,51为研究确定的平均CLCR。
- 模拟中,推荐预防剂量达到目标AUC的概率不足,尤其CLCR<50 mL/min的肾功能受损患者。
关键数值与推荐
- 目标AUC为40-50 mg·h/L。
- CLCR<50 mL/min时,推荐剂量方案达到目标AUC的概率不足。
临床怎么用
- 肾移植受者口服缬更昔洛韦预防CMV时,应按肾功能校正并考虑高于推荐剂量。
- 尤其CLCR<50 mL/min者,需关注推荐剂量下AUC达标概率不足的问题。
局限性
- 回顾性研究设计。
- 尚未确立TDM目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Valganciclovir is used as oral prophylaxis for cytomegalovirus (CMV) infection in kidney transplant recipients. However, limited pharmacokinetic data exist to guide dosing in this patient group. This study aimed to describe the population pharmacokinetics of valganciclovir in a large sample of kidney transplant recipients and predict optimal dosing based on Monte Carlo simulations. METHODS: Therapeutic drug monitoring (TDM) data from adult kidney transplant recipients who received valganciclovir prophylaxis during a 10-year study period were collected retrospectively. A non-parametric pharmacokinetic analysis and Monte Carlo simulations to determine the probabilities of reaching an area under the drug concentration-time curve (AUC) target of 40-50 mg·h/L with various dosing regimens at different levels of renal function were conducted using the Pmetrics™ package for R. RESULTS: This study included 792 ganciclovir concentration measurements derived from 97 patients. A one-compartment oral absorption model best described the data. The final covariate model was as follows: CL(ganciclovir) = TVCL × (CLCR/51)0.75, where CL is the clearance, TVCL is the typical value of ganciclovir clearance, creatinine clearance (CLCR) according to the Cockcroft-Gaultt equation and 51 is the mean CLCR determined in the study. In the simulations, the probability of reaching the targeted AUC was insufficient when using the recommended dosing regimens for prophylaxis, especially in patients with impaired renal function at CLCR < 50 mL/min. CONCLUSIONS: Higher doses of valganciclovir corrected to renal function are suggested for use as oral prophylaxis for CMV infection in kidney transplant recipients. Further study is required to establish TDM targets to ensure adequate drug concentrations while avoiding potentially toxic drug exposures.
引用
- Tängdén T, Cojutti PG, Roberts JA, et al. Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. Clin Pharmacokinet. 2018. PMID: 29546589. doi:10.1007/s40262-018-0638-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。